Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-05-10 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物2021年年度股东大会会议材料
AGM Information Classification · 100% confidence The document is titled as '2021年年度股东大会会议材料' which translates to '2021 Annual General Meeting (AGM) Meeting Materials' for Autobio Diagnostics Co., Ltd. It contains detailed agenda items, reports to be submitted to the AGM, meeting procedures, voting details, and various reports such as the Board of Directors' work report, Supervisory Board work report, financial reports, and governance-related proposals. The content is consistent with materials prepared and distributed for an Annual General Meeting, including procedural documents, reports for shareholder review, and voting items. There is no indication that this is the full Annual Report (10-K) or a simple announcement of a report publication. The document length is substantial (15,000 characters) and contains detailed meeting materials, not just a brief notice or certification. Therefore, the document fits the category of AGM Information (AGM-R).
2022-05-10 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amounts paid, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but reports on the status of the company's buyback activity. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's share repurchase activities.
2022-05-05 Chinese
安图生物独立董事关于公司第四届董事会第四次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding their prior approval opinion on the reappointment of the company's 2022 audit firm. It references regulatory rules related to independent directors and audit practices but does not contain any financial data or audit results itself. The document is short (422 characters) and serves as an announcement or opinion related to audit matters rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit firm appointment and compliance with audit regulations.
2022-04-26 Chinese
安图生物关于续聘公司2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm for the company's 2022 fiscal year. It details the audit firm's qualifications, personnel, independence, audit fees, and the approval process by the audit committee, independent directors, and the board of directors. The document does not contain actual audit reports or financial statements but is a formal announcement about the selection and continuation of the audit firm. The document length is 3211 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR) as it relates specifically to audit firm appointment and audit-related information, but it is not a full annual report or audit report itself. However, since it is an announcement about the audit firm appointment and not the audit report itself, it is best classified as Audit Report / Information (AR).
2022-04-26 Chinese
安图生物章程（2022年4月修订）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 郑州安图生物工程股份有限公司. It contains detailed chapters about the company's organizational structure, shareholder rights, board of directors, management, financial accounting system, profit distribution, auditing, and other governance-related matters. It references Chinese company law and securities law, and includes detailed provisions on shareholder meetings, board responsibilities, share issuance, and other corporate governance topics. There is no indication that this is a financial report, earnings release, or announcement. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full governance report, not a brief announcement or regulatory filing.
2022-04-26 Chinese
安图生物2021年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the year 2021 by Zhengzhou Antu Bioengineering Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. The document is short (1528 characters) and focuses on the dividend distribution proposal, which is to be submitted to the annual shareholders meeting for approval. It does not contain full financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is specifically about the dividend amount and distribution plan, which fits the definition of a Notice of Dividend Amount (DIV).
2022-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.